Update on Janus kinase antagonists in inflammatory bowel disease.

Abstract

Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target the activity of specific JAKs and to offer a targeted mechanism of action without risk of immunogenicity. Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.

• Authors: Brigid S Boland, William J Sandborn, John T Chang
• Journal: Gastroenterology clinics of North America (Gastroenterol Clin North Am) Vol. 43 Issue 3 Pg. 603-17 (Sep 2014) ISSN: 1558-1942 [Electronic] United States
• PMID: 25110261 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• Piperidines
• Protein Kinase Inhibitors
• Pyrimidines
• Pyrroles
• tofacitinib
• Janus Kinases

Topics

• Animals
• Dyslipidemias (chemically induced)
• Humans
• Inflammatory Bowel Diseases (drug therapy)
• Janus Kinases (antagonists & inhibitors, deficiency)
• Opportunistic Infections (chemically induced)
• Piperidines (adverse effects, therapeutic use)
• Protein Kinase Inhibitors (adverse effects, therapeutic use)
• Pyrimidines (adverse effects, therapeutic use)
• Pyrroles (adverse effects, therapeutic use)
• Signal Transduction (drug effects)